This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA was commissioned by AstraZeneca to investigate the economic and societal burden associated with Acute Coronary Syndrome (ACS) in Canada. This short paper represents a summary of the full report.
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...
“I am pleased to welcome Chris to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “His areas of expertise include...
Tim Wilsdon moderates the panel discussion titled “The Economic impact of living with a rare disease in APAC and LATAM – Regional solutions to inform a Global...
As the center of life sciences innovation increasingly shifts to China, companies must be ready for a more complex international arbitration landscape. In this...
